{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '2101 Cottontail Lane',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 37.15,
 'askSize': 1300,
 'averageDailyVolume10Day': 176912,
 'averageVolume': 547740,
 'averageVolume10days': 176912,
 'beta': None,
 'beta3Year': None,
 'bid': 35.5,
 'bidSize': 900,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Somerset',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 37.12,
 'dayLow': 35,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -22.599,
 'enterpriseToRevenue': 58.964,
 'enterpriseValue': 3622188032,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 38.240856,
 'fiftyTwoWeekHigh': 43.24,
 'fiftyTwoWeekLow': 34.57,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 24213000,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 650,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': None,
 'heldPercentInstitutions': None,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/legendbiotech.com',
 'longBusinessSummary': 'Legend Biotech Corporation, a clinical-stage '
                        'biopharmaceutical company, engages in the discovery '
                        'and development of novel cell therapies for oncology '
                        'and other indications. Its lead product candidate, '
                        'LCAR-B38M/JNJ-4528, is an autologous CAR-T cell '
                        'therapy that targets the B-cell maturation antigen. '
                        'The company is conducting multiple clinical trials to '
                        'evaluate LCAR-B38M/JNJ-4528 as an earlier line of '
                        'therapy for multiple myeloma (MM), as well as a '
                        'comparison of the treatment with standard triplet '
                        'therapy in Revlimid-refractory MM. It also has a '
                        'broad portfolio of earlier-stage autologous product '
                        'candidates targeting various cancers, including '
                        'non-hodgkins lymphoma (NHL), acute myeloid leukemia, '
                        'and T cell lymphoma. In addition, the company is '
                        'developing an allogeneic CAR-T product candidate '
                        'targeting CD20 for the treatment of NHL, which is '
                        'currently in an investigator-initiated Phase 1 '
                        'clinical trial in China. Further, it has various '
                        'product candidates in early preclinical and clinical '
                        'development for the treatment of solid tumors, as '
                        'well as infectious diseases. The company was founded '
                        'in 2014 and is based in Somerset, New Jersey. Legend '
                        'Biotech Corporation is a subsidiary of Genscript '
                        'Biotech Corporation.',
 'longName': 'Legend Biotech Corporation',
 'market': 'us_market',
 'marketCap': 4692813312,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_552805228',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -164770000,
 'nextFiscalYearEnd': 1640908800,
 'open': 36.78,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '732 317 5050',
 'previousClose': 37.15,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 76.39162,
 'profitMargins': -2.6822,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 37.12,
 'regularMarketDayLow': 35,
 'regularMarketOpen': 36.78,
 'regularMarketPreviousClose': 37.15,
 'regularMarketPrice': 36.78,
 'regularMarketVolume': 302057,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 129243000,
 'sharesPercentSharesOut': 0.0025,
 'sharesShort': 121791,
 'sharesShortPreviousMonthDate': None,
 'sharesShortPriorMonth': None,
 'shortName': 'Legend Biotech Corporation',
 'shortPercentOfFloat': None,
 'shortRatio': 0.07,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'LEGN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 38.240856,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ccaf9204-94bb-3c10-bdb1-a5d800652e71',
 'volume': 302057,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.legendbiotech.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '08873'}